Breaking News :

Glenmark Pharmaceuticals Announces Poster Presentations on Bispecific Antibodies

5/28/2018

Mumbai,  Glenmark Pharmaceuticals, a global pharmaceutical company, on Monday announced the presentation of data from two assets in its immuno-oncology portfolio at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). These presentations include preclinical and translational data on GBR 1302, a HER2xCD3 bispecific antibody, and a Trials in Progress (TIP) poster on GBR 1342, a CD38xCD3 bispecific antibody. GBR 1302 is Glenmark's lead immuno-oncology candidate, currently in the first-in-human trial to determine maximum tolerated dose (MTD) in an all-comers population of patients with a variety of HER2 positive cancers. This Phase 1 trial is being expanded to explore higher doses of GBR1302 and to examine potential clinical benefit of once-weekly dosing regimen. Enrollment for the GBR 1302 clinical trial is currently ongoing in the U S and Germany.In parallel, an ex vivo translational study has recently been completed utilizing a fully human, clinically validated diagnostic platform that delivers treatment response predictions to identify responder context to GBR 1302 in metastatic breast and gastric cancer tissue biopsies,company said in a filing with BSE. The translational study further investigates the novel Mechanism of Action (MOA) of GBR 1302 in a tumor microenvironment and its impact on expansion of memory and effector CD8+/CD4+ T cells to inform precise patient selection. The translational study also addresses the effect of T cell engagers in combination with check point inhibitors (e.g, anti-PD1/PDL1). 'By relying on a combination of translational data and clinical adaptive design, Glenmark is rapidly advancing potential first-in-class immuno-oncology candidates,' said Fred Grossman, President and Chief Medical Officer at Glenmark Pharmaceuticals.'We are pleased to share these emerging data and updates on our immuno-oncology pipeline at the ASCO Annual Meeting.' Based on preliminary data from the Phase 1 clinical study, and ex vivo translational studies, a Phase 1b/2 study is currently being designed and will include an expansion cohort of HER2 positive metastatic breast cancer patients. The expansion cohort will evaluate the safety, pharmacokinetics and antitumor activity of GBR 1302 and is intended to generate robust and comprehensive translational data.

Opinions expressed in the comments are not reflective of Central Chronicle. Comments are moderated automatically.